Gilead to Acquire CAR-T Specialist Arcellx for $7.8 Billion
Gilead will acquire CAR-T specialist Arcellx for $7.8 billion in an all-cash transaction marking one of its largest oncology deals this year. The agreement adds Arcellx’s lead CAR-T candidate to Gilead’s pipeline and awaits shareholder and regulatory approvals.
1. Acquisition Terms
Gilead has agreed to purchase all outstanding shares of Arcellx in an all-cash deal valued at $7.8 billion. The transaction will transfer control of Arcellx’s assets to Gilead and is subject to customary shareholder and antitrust approvals before closing.
2. Pipeline Expansion
Arcellx’s lead program, a BCMA-directed CAR-T therapy in Phase 1/2 trials for multiple myeloma, becomes part of Gilead’s oncology portfolio. The acquisition also brings preclinical CAR-T constructs targeting solid tumors into Gilead’s broader cell therapy research efforts.
3. Strategic Fit
This deal accelerates Gilead’s push into cell therapy, complementing its existing CAR-T franchise and strengthening its position against competitors in hematologic malignancies. Integrating Arcellx’s synthetic biology platform aims to enhance manufacturing efficiency and pipeline diversity.
4. Next Steps and Timeline
Following signing, both companies will seek votes from their shareholders and file required documents with regulatory bodies. Subject to approvals, the parties anticipate closing the transaction later this year, after which integration planning will commence.